New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
出版年份 2011 全文链接
标题
New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome
作者
关键词
-
出版物
Hematology-American Society of Hematology Education Program
Volume 2011, Issue 1, Pages 550-555
出版商
American Society of Hematology
发表日期
2011-12-08
DOI
10.1182/asheducation-2011.1.550
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms
- (2017) O. Odenike et al. JOURNAL OF CLINICAL ONCOLOGY
- Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes
- (2011) Lewis R. Silverman et al. CANCER
- Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia
- (2011) Guillermo Garcia-Manero et al. JOURNAL OF CLINICAL ONCOLOGY
- Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
- (2011) Michael Lübbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine combined with gemtuzumab ozogamicin in patients with relapsed/refractory acute myeloid leukemia
- (2011) Ulas Darda bayraktar et al. LEUKEMIA & LYMPHOMA
- Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes
- (2010) Mikkael A. Sekeres et al. AMERICAN JOURNAL OF HEMATOLOGY
- 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors after Allogeneic Bone Marrow Transplantation
- (2010) Javier Bolaños-Meade et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
- (2010) J. Choi et al. BLOOD
- Repression of Id2 expression by Gfi-1 is required for B-cell and myeloid development
- (2010) H. Li et al. BLOOD
- Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells
- (2010) X. Wang et al. BLOOD
- Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia
- (2010) O. Goodyear et al. BLOOD
- Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
- (2010) Pierre Fenaux et al. BRITISH JOURNAL OF HAEMATOLOGY
- Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy
- (2010) Michael Grövdal et al. BRITISH JOURNAL OF HAEMATOLOGY
- Activity of azacitidine in chronic myelomonocytic leukemia
- (2010) Rubens Costa et al. CANCER
- Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome
- (2010) Marcos de Lima et al. CANCER
- Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
- (2010) John F. Seymour et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
- (2010) Mikkael A. Sekeres et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
- (2010) W. Blum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7
- (2009) I. Furlan et al. BLOOD
- Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation setting
- (2009) L. I. Sanchez-Abarca et al. BLOOD
- Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
- (2009) T. E. Fandy et al. BLOOD
- 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis
- (2009) A Czibere et al. BONE MARROW TRANSPLANTATION
- Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
- (2009) M Lübbert et al. BONE MARROW TRANSPLANTATION
- Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
- (2009) M Lübbert et al. BONE MARROW TRANSPLANTATION
- 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
- (2009) T Field et al. BONE MARROW TRANSPLANTATION
- Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2′-deoxycytidine
- (2009) Irina Daurkin et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Correction of the Abnormal Trafficking of Primary Myelofibrosis CD34+ Cells by Treatment with Chromatin-Modifying Agents
- (2009) X. Wang et al. CANCER RESEARCH
- Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
- (2009) David P. Steensma et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Hematopoietic Stem-Cell Transplantation for Patients 50 Years or Older With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia
- (2009) ZiYi Lim et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
- (2009) Pierre Fenaux et al. LANCET ONCOLOGY
- Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy
- (2008) L. Hambach et al. BLOOD
- A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
- (2008) A Quintás-Cardama et al. LEUKEMIA
- Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial
- (2008) Sucha Nand et al. LEUKEMIA & LYMPHOMA
- Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)
- (2007) P.W. Wijermans et al. LEUKEMIA RESEARCH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started